nach oben

Erschienen in:

01.07.2011 | Original Article

Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma

verfasst von: Hidenari Nagai, Teppei Matsui, Masahiro Kanayama, Noritaka Wakui, Kouichi Momiyama, Manabu Watanabe, Yoshinori Igarashi, Yasukiyo Sumino

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We have previously shown that continuous intra-arterial combination chemotherapy (IACC) might be more effective for advanced hepatocellular carcinoma (aHCC) in patients with HCV-related liver cirrhosis (C-LC) or alcoholic liver cirrhosis (A-LC) than in patients with HBV-related LC (B-LC). However, it is still unknown whether IACC actually improves the prognosis of aHCC patients with liver cirrhosis (LC), because it is difficult to perform a randomized controlled trial for patients with a poor prognosis. The aim of this study was to retrospectively assess the influence of IACC on the prognosis of aHCC.

Methods

Fifty-eight adult Japanese patients who had aHCC and LC underwent repeated trans-arterial chemoembolization (TACE) without IACC between 1990 and 1997 at our hospital (group T), while 43 patients with aHCC and LC received IACC between 2000 and 2008 after undergoing several TACE sessions (group R). The Japan Integrated Staging score (JIS score) of each patient was ≥ 3 at the time of presentation, except for patients with tumor thrombi involving the first or subsequent portal vein branches or those with tumor invasion of the inferior vena cava. The same IACC regimen was repeated for as long as possible in group R.

Results

In group T, 13 patients had B-LC, 37 patients had C-LC, and 8 patients had A-LC, while the respective numbers were 14, 21, and 8 in group R. The median survival time (MST) was 248 days for patients with C-LC in group T and 708 days for those in group R, while it was 253 days for patients with A-LC in group T and 593 days for those in group R. There were significant differences of survival between the two groups. However, MST was 369 days for patients with B-LC in group T and 782 days for those in group R, without a significant difference. In group R, a complete or partial response was achieved after 4 weeks of chemotherapy in 14.3% of patients with B-LC versus 42.9% of patients with C-LC and 37.5% of patients with A-LC.

Conclusions

In LC patients with a JIS score > 3 at diagnosis, multimodal therapy with IACC after TACE prolongs the MST of C-LC or A-LC patients compared with TACE alone, although it does not improve the MST of patients with B-LC.

Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRef

Yu MC, Yuan J-M (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72–S78PubMedCrossRef

Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16PubMedCrossRef

Chuang VP, Wallace S (1981) Hepatic arterial embolization in the treatment of hepatic neoplasms. Radiology 140:51–58PubMed

Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401PubMed

Lin DY, Liaw YF, Lee TY et al (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 94:453–456PubMed

Ikeda K, Kumada H, Saitoh S et al (1991) Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 68:2150–2154PubMedCrossRef

Llovet JM, Real MI, Montana X et al (2002) Barcelona liver cancer group. Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739PubMedCrossRef

Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRef

10.

Takayasu K, Arii S, Ikai I et al (2006) Liver cancer study group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 131:461–469PubMedCrossRef

11.

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Onishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef

12.

Nagasue N, Yukaya H, Hamada T, Hirosue S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461–1465PubMedCrossRef

13.

Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kirishima S, Suga T, Takahashi M (1995) The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295–299PubMedCrossRef

14.

Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Takahisa Sakai, Deguchi M, Ohmori S, Nakano T (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719–1722PubMed

15.

Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Takikawa K (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncology Report 6:587–591

16.

Nagai H, Sumino Y (2008) Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anticancer Drug Discov 3:220–226PubMedCrossRef

17.

Nagai H, Kanayama M, Higami K et al (2007) Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 13(2):280–284PubMed

18.

Kanayama M, Nagai H, Sumino Y (2009) Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 64:109–114PubMedCrossRef

19.

Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109PubMedCrossRef

20.

Moreno-Aspitia A, Morton RF, Hillman DW et al (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central cancer treatment group and Mayo Clinic Trial N0336. J Clin Oncol 27:11–15PubMedCrossRef

21.

Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300PubMedCrossRef

22.

Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33:S134–S138PubMedCrossRef

23.

Wakasa K, Sakurai M, Kuroda C et al (1990) Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 65:913–919PubMedCrossRef

24.

Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endotherial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRef

25.

Ferrara N, Gerber HP, LeCounter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef

26.

Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune response to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341PubMedCrossRef

27.

Shevach EM (2001) Certified professionals: CD4⁺ CD25⁺ suppressor T cell. J Exp Med 193:F41–F46PubMedCrossRef

28.

Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4 + CD25 + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 31:1247–1254PubMedCrossRef

29.

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4 + CD25 + T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285–1294PubMedCrossRef

30.

Mosmann TR, Coffman RL (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145–173PubMedCrossRef

31.

O’Garra A (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275–283PubMedCrossRef

32.

Roitt I (ed) (1997) Essential immunology, 9th edn. Blackwell Science, Malden

33.

Kuby J, Cameron J, Todd C, Mitchell J (2000) Immunology, 4th edn. Freeman and Company, New York

34.

Kobayashi M, Kobayashi H, Polland RB et al (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869–5873PubMed

35.

Zitvogel L, Mayordomo JI, Tjandrawan T et al (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97PubMedCrossRef

36.

Tsung K, Meko JB, Peplinski GR et al (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359–3365PubMed

37.

Weiner GJ, Liu HM, Wooldridge JE et al (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833–10837PubMedCrossRef

38.

Hu H-M, Urba WJ, Fox BA (1998) Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from Type 2 to a type 1 cytokine profile. J Immunol 161:3033PubMed

39.

Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K (2008) Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. Cancer Chemother Pharmacol 62:959–963PubMedCrossRef

40.

Momiyama K, Nagai H, Sumino Y (2009) Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol 64:271–277PubMedCrossRef

Titel: Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma
verfasst von: Hidenari Nagai
Teppei Matsui
Masahiro Kanayama
Noritaka Wakui
Kouichi Momiyama
Manabu Watanabe
Yoshinori Igarashi
Yasukiyo Sumino
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1465-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma